key: cord-0999505-7wv31gzg
authors: Nishimoto, Mitsutaka; Sogabe, Nobuhiro; Hino, Masayuki
title: Visceral disseminated varicella zoster virus infection following COVID‐19 vaccination in an allogeneic stem cell transplant recipient
date: 2022-03-02
journal: Transpl Infect Dis
DOI: 10.1111/tid.13810
sha: ea33dc7b43414fce2b1e322080597562b9437f3b
doc_id: 999505
cord_uid: 7wv31gzg

nan

Herpes zoster is a relatively common disease caused by the reactivation of latent varicella zoster virus (VZV), human herpes type 3, in compromised patients. 1 Visceral disseminated VZV infection, a type of VZV disease without typical skin lesions, sometimes occurs in transplant recipients. 2 The presence of graft-versus-host disease, ongoing use of immunosuppressants, and lymphoid malignancies have been reported as risk factors for the reactivation of VZV after allogeneic stem cell transplantation (allo-SCT). 3, 4 However, there are extremely limited reports of cases of disseminated VZV infection following coronavirus disease 2019 (COVID-19) vaccination. It is possible the shift to specific immunity mediated by messenger RNA (mRNA)-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) weakens non-specific immunity against non-targeted viruses in an immunocompromised host. [5] [6] [7] We herein describe a case of visceral disseminated VZV infection following COVID-19 vaccination that occurred concurrently with a decrease in the non-specific CD8+ T-cell count in an allo-SCT recipient.

A 72-year-old man with acute myelomonocytic leukemia received cord blood transplantation with reduced intensity conditioning, consisting of fludarabine (180 mg/m 2 ), melphalan (80 mg/m 2 ), and antithymocyte globulin (2.5 mg/kg). Tacrolimus and short-term methotrexate were administered as prophylaxis against graft-versus-host disease.

Oral acyclovir (200 mg, daily) was given as prophylaxis against herpes zoster. After achieving engraftment, tacrolimus was tapered and dis- While visceral disseminated VZV infection following allo-SCT has been reported, 2 little is known about its relevance to COVID-19 vaccination. There is only one reported case of disseminated VZV infection, which occurred 3 days after the second dose of an mRNA-based vaccine in a patient who had received cord blood transplantation. 8 In line with the previous case, disseminated VZV infection occurred despite the discontinuation of tacrolimus and glucocorticosteroids, suggesting COVID-19 vaccination may have triggered the reactivation of VZV in the current case. In addition, the cessation of prophylactic acyclovir 2 months before vaccination may have failed to prevent the reactivation of VZV, 9 and the patient's old age and comorbidity of type 2 diabetes mellitus may have also been associated with reactivation.

Although the reactivation of VZV following COVID-19 vaccination was not reported in initial clinical trials, 10 an observational study in Israel showed an increased risk of herpes zoster in vaccinated patients. 11 Causality between VZV infection and COVID-19 vaccination was recently suggested in a case series. In a systemic review of case reports describing 91 cases of VZV following COVID-19 vaccination with three types of vaccines (Pfizer-BNT162b2, AstraZeneca-ChAdOx1-nCoV19, and Moderna-mRNA-1273), the mean day of onset was 3.6-9 days after vaccination. 7 In the setting of other vaccines against inactivated hepatitis A, influenza virus, rabies, and Japanese encephalitis virus, the reactivation of herpesvirus infection was observed; however, this was uncommon. 12 Furthermore, in a study of school-aged children, the administration of an inactivated influenza vaccine was suggested to be associated with an increased risk of noninfluenza respiratory virus infection. 13 The mechanisms of reactivation of VZV after COVID-19 vaccination has yet to be determined. One possible hypothesis is that the temporal massive shift of naïve CD8+ T cells mediated by mRNAbased vaccines contributes to the disturbance of VZV-specific CD8+ T-cell immunity, resulting in the failure to control VZV activation. [5] [6] [7] Patients with severe COVID-19 have been reported to experience an immunosuppressive state with a decrease of T lymphocytes within 2 weeks after infection. 14 Similar to the disease, mRNA-based vaccines can temporarily cause T-cell immune dysfunction after initial rapid hyperactivation followed by exhaustion. Moreover, lower CD8+ T-cell counts after vaccination seems to be related to higher seroconversion of anti-SARS-COV-2 immunoglobin G (IgG) antibodies in allo-SCT recipients. 15 Although we could not analyze the subsets of CD8+ T cells (e.g., naïve, effector, or memory T cells) in detail, the transient decrease of CD8+ T cells after vaccination reflects the alteration of immunity by mRNA-based vaccines. Further studies should be conducted to validate this hypothesis.

The outcome of visceral disseminated VZV infection is dismal after allo-SCT. 2 On the other hand, in the current case, a relatively rapid response to acyclovir was obtained and the symptoms resolved without any sequelae, including post-herpetic neuralgia. The transient, but NISHIMOTO ET AL.

not profound, immune disturbance induced by mRNA-based vaccines along with immediate treatment with antiviral agents may prevent progression to fulminant VZV infection.

In conclusion, we encountered a case of visceral disseminated VZV infection following COVID-19 vaccination in an allo-SCT recipient.

We should bear in mind that reactivation of VZV infection may occur after COVID-19 vaccination, particularly in transplant recipients. The decrease of CD8+ T cells after vaccination can be a surrogate marker of viral reactivation after allo-SCT. Causality between COVID-19 vaccination and reactivation of VZV has not yet been confirmed and further investigations are warranted to elucidate the precise mechanism and relevance of VZV reactivation after the administration of an mRNAbased vaccine.

We thank Dr. Masatomo Kuno, Yosuke Makuuchi, Hiroshi Okamura, Yasuhiro Nakashima, Hideo Koh, and Hirohisa Nakamae for taking care of the patient.

Masayuki Hino received research funding from Pfizer, speaker's honoraria from Pfizer and Sanofi. The other authors have no conflicts of interest to declare.

Written informed consent was obtained from the patient for publication of this article. 

Incidence of herpes zoster in patients with altered immune function

Visceral varicella zoster virus infection after allogeneic stem cell transplantation

Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders

Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients

Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series

Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines

Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports

Disseminated varicella-zoster virus infections following messenger RNAbased COVID-19 vaccination

The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation

Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials

Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting

Reactivation of herpesvirus infections after vaccinations?

Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine

Can COVID-19 increase the risk of herpes zoster? A narrative review

Immunological response against SARS-COV-2 after BNT162b2 vaccine administration is impaired in allogeneic but not in autologous stem cell transplant recipients

Visceral disseminated varicella zoster virus infection following COVID-19 vaccination in an allogeneic stem cell transplant recipient